Tue, Jul 13, 2021

Life Sciences Webcast Series

Kroll recently hosted a webcast series that brought together our leading experts and industry leaders to share insights on trends, valuation, technology, intellectual property (IP), risk and regulation in the life sciences industry. Please see below for more details on each session and a link to the event replays.

Key Insights and Trends

As big pharma and biotech conglomerates continue to seek growth following the COVID-19 pandemic, our experts provide insights on what will shape the future of the life sciences industry and dissect the key drivers of M&A activity.

Key Insights

Deal trends and investment opportunities
Digitalization and remote engagement in healthcare
The importance of environmental, social, and corporate governance (ESG)

Panelists

Andreas Chrysostomou, Managing Director, Duff & Phelps
Brooks Dexter, Managing Director, Duff & Phelps
Andrew Probert, Managing Director, Duff & Phelps
James D’Arecca, Chief Financial Officer, TherapeuticsMD

Biotechnology Purchase Accounting Valuation

Purchase accounting valuation in the biotechnology industry can be particularly challenging. Understanding the intricacies of biotechnology valuation and having command best practices is key to successfully navigating the valuation process for all stakeholders. Duff & Phelps’ Life Sciences valuation advisory team walk you through a purchase price allocation for a hypothetical biotechnology company based on real world experience.

Key Insights

Key considerations and intricacies regarding unit of account decisions in product/product candidate valuation.
Unique inventory valuation considerations in biotechnology acquisitions
Valuation of biotechnology collaborations/licensing arrangements
Contingent liability and contingent consideration valuation
Navigating the audit process and documentation

Panelists

Andreas Chrysostomou, Managing Director, Duff & Phelps
Jonathan Goldblatt, Managing Director, Duff & Phelps
Frank Deluca, Director, Duff & Phelps
David Nadel, Director, Duff & Phelps

The Impact of Technology

Technology continues to impact the relationship between businesses and their stakeholders, with data exchange, digital service provision and innovation all driving discussion. Our panel of experts address data-driven approaches to patient care, the impact of technology on regulation, and IP, data privacy and cyber security issues in the healthcare and life sciences industry.

Key Insights

Using technology to analyze data and provide better patient care
The impact of regulation on the modernization of compliance programs
Safeguarding IP with privacy, cyber and IT procedures
Balancing data privacy, cyber and the efficient exchange of patient data
Protecting assets against cyber-attacks and unforced errors

Panelists

Alpa Kamdar, Managing Director, Duff & Phelps
Stacy Scott, Managing Director, Kroll

Intellectual Property – Management, Protection and Enforcement

Intellectual Property – Management, Protection and Enforcement

Our panel of leading attorneys discuss current issues facing the life sciences industry with respect to the management, protection and enforcement of IP rights in the UK, Europe and the U.S.

Key Insights

Cross-border challenges
The UK and Europe post Brexit
The International Trade Commission
The impact of biosimilars on the IP landscape

Panelists

Pauline Booth, Managing Director, Duff & Phelps
Barbara Fiacco, Partner, Foley Hoag
Dr. Penny Gilbert, Partner, Powell Gilbert LLP, London
PJ McCarthy, Partner, Goodwin

The Role of Regulation

The Role of Regulation

Chris Campbell, Chief Strategist at Kroll, Michael Kiely, President of U.S. Government Affairs at UPS and John Selib, Senior Vice President, Global Policy & Public Affairs at Pfizer, sat down for a fireside chat on the impact of regulation on the life sciences industry as well as emerging hot topics.

Key Insights

Will regulators be globally aligned?
ESG Regulation under the Biden Administration
Is there potential for industry and regulators to work closely in sharing ‘real-time’ data
Critical emerging trends and hot topics

Panelists

Chris Campbell, Chief Strategist, Kroll
John Selib, Senior Vice President, Global Policy & Public Affairs, Pfizers
Michael Kiely, President of U.S. Government Affairs, UPS

Navigating the Elevated Risk Environment

Navigating the Elevated Risk Environment

This discussion provides insights on how the post-COVID-19 environment is challenging for the pharmaceutical and medical device industries. The increased public scrutiny and rapid development of and changes to these industries over the past year amplifies existing operational risks. Our panel of experts addressed evolving risks challenging life sciences global supply chains, including around price gouging rules, how to identify risk exposure and navigate the complex regulatory landscape.

Key Insights

Developing strategies that de-risk businesses and operating models
Overview of various U.S. and a selection of other government policies and actions impacting the life science’s global supply chains, including for example, price gouging rules
Anticipating and addressing increased costs of compliance
Strengthening procedures around risk management

Panelists

Roeland Van Aelst, EMEA Lead Third Party Intermediary Ethics & Compliance, Johnson & Johnson
John Ingrassia, Senior Counsel, Proskauer Rose LLP
Tasneem Azad, Managing Director, Duff & Phelps, a Kroll Business
Daniel Hartnett, Associate Managing Director, Kroll

Valuation

Valuation of businesses, assets and alternative investments for financial reporting, tax and other purposes.

Service Link

Corporate Finance and Restructuring

Middle Market M&A, Strategic Advisory, Debt Advisory and Private Capital Markets, Restructuring and Insolvency Services, Financial Due Diligence, Fairness Opinions, Solvency Opinions and ESOP/ERISA Advisory.

Service Link

Compliance Risk and Diligence

The Kroll Investigations, Diligence and Compliance team partners with clients to anticipate, detect and manage regulatory and reputational risks associated with global ethics and compliance obligations.

Service Link

Forensic Investigations and Intelligence

The Kroll Investigations, Diligence and Compliance team are experts in forensic investigations and intelligence, delivering actionable data and insights that help clients worldwide make critical decisions and mitigate risk.

Service Link

Transaction Advisory Services

Seamless analytical advisory through the deal continuum, from transaction origination to closing.

Service Link

Cyber Risk

Incident response, digital forensics, breach notification, managed detection services, penetration testing, cyber assessments and advisory.

Service Link

Enterprise Security Risk Management

Kroll’s Enterprise Security Risk Management practice provides expert guidance and advisory services to our global clientele as they navigate the most challenging and emerging security and threat-related issues.

Service Link

Financial Services Compliance and Regulation

End-to-end governance, advisory and monitorship solutions to detect, mitigate, drive efficiencies and remediate operational, legal, compliance and regulatory risk.

Service Link